Ascendis Pharma A/S (ASND) Form 6-K — Sep 9, 2026
Ascendis Pharma A/S announced on September 9, 2026, Week 52 data from the open-label sentinel cohort of the reACHin Trial showing that once-weekly TransCon CNP (navepegritide) provided stabilization or improvement in foramen magnum stenosis and linear growth benefits in infants with achondroplasia aged 0 to <2 years. The data were presented at ESPE 2026, the European Society for Paediatric Endocrinology annual meeting. In the cohort of seven infants (mean age 11.7 months), the Achondroplasia Foramen Magnum Score was stable or improved in all children, mean change in foramen magnum sagittal diameter was +3.15 mm, and no decompression surgeries occurred during the 52-week period.
Key figures
- Dose Ug Kg Week
- 100 µg/kg/week
- Mean Age Months
- 11.7
- Data Presented At
- ESPE 2026
- Sentinel Cohort Size
- 7
- Supine Length ZScore Change
- 0.42
- Double Blind Enrollment Target
- 66
- Treatment Related Adverse Events
- 0
- Annualized Growth Velocity Cm Per Year
- 9.9
- Decompression Surgeries During52 Weeks
- 0
- Foramen Magnum Sagittal Diameter Change Mm
- 3.15
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.